Ignacio Toledano - Laboratorios Farmaceuticos Deputy Sec

All Insiders . USA . 
Stock . Laboratorios Farmaceuticos Rovi . Stakeholders . Insider . Ignacio Toledano
LABFF Stock  USD 90.61  0.00  0.00%   

Insider

Ignacio Toledano is Deputy Sec of Laboratorios Farmaceuticos Rovi
Phone34 91 021 30 00
Webhttps://www.rovi.es

Laboratorios Farmaceuticos Management Efficiency

The company has return on total asset (ROA) of 0.1844 % which means that it generated a profit of $0.1844 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.3919 %, meaning that it generated $0.3919 on every $100 dollars invested by stockholders. Laboratorios Farmaceuticos' management efficiency ratios could be used to measure how well Laboratorios Farmaceuticos manages its routine affairs as well as how well it operates its assets and liabilities.
Laboratorios Farmaceuticos Rovi has accumulated 52.52 M in total debt with debt to equity ratio (D/E) of 0.18, which may suggest the company is not taking enough advantage from borrowing. Laboratorios Farmaceuticos has a current ratio of 1.73, which is within standard range for the sector. Debt can assist Laboratorios Farmaceuticos until it has trouble settling it off, either with new capital or with free cash flow. So, Laboratorios Farmaceuticos' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Laboratorios Farmaceuticos sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Laboratorios to invest in growth at high rates of return. When we think about Laboratorios Farmaceuticos' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Shaojing TongInnoCare Pharma Limited
51
Sren NiegelALK Abell AS
52
Zhenyu LiuGenscript Biotech
46
Lani MorvanZealand Pharma AS
N/A
Soren JelertALK Abell AS
51
Weihui ShaoGenscript Biotech
43
Adam MDZealand Pharma AS
49
Ye MSGenscript Biotech
55
Davy OuyangInnoCare Pharma Limited
N/A
Renbin ZhaoInnoCare Pharma Limited
54
Ravinder ChahilZealand Pharma AS
N/A
Christina BredalZealand Pharma AS
38
Sean MDInnoCare Pharma Limited
N/A
Miles GuralnickALK Abell AS
N/A
Mads KronborgZealand Pharma AS
N/A
Brian MinGenscript Biotech
N/A
XiangYang ZhangInnoCare Pharma Limited
61
Junsu WangInnoCare Pharma Limited
47
Euan ThomsonCarl Zeiss Meditec
60
Martin WiechmannCarl Zeiss Meditec
N/A
Jisong CuiInnoCare Pharma Limited
60
Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, production, and sale of pharmaceutical products in Spain, European Union, OECD countries, and internationally. Laboratorios Farmaceticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L. Laboratorios Farmaceuticos operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 1852 people. Laboratorios Farmaceuticos Rovi [LABFF] is a Pink Sheet which is traded between brokers as part of OTC trading.

Management Performance

Return On Equity0.39
Return On Asset0.18

Laboratorios Farmaceuticos Leadership Team

Elected by the shareholders, the Laboratorios Farmaceuticos' board of directors comprises two types of representatives: Laboratorios Farmaceuticos inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Laboratorios. The board's role is to monitor Laboratorios Farmaceuticos' management team and ensure that shareholders' interests are well served. Laboratorios Farmaceuticos' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Laboratorios Farmaceuticos' outside directors are responsible for providing unbiased perspectives on the board's policies.
Ignacio Toledano, Deputy Sec
Francisco Garca, HR Mang
Gabriel Fernandez, Sec
Juan Encina, CEO Pres
Fernando Morales, Director Sales
Rosario Prez, Marketing Mang
Ivan Encina, Second Devel
Javier Encina, First CFO
Mercedes Snchez, Legal Mang

Laboratorios Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Laboratorios Farmaceuticos a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity0.39
Return On Asset0.18
Profit Margin0.23 %
Operating Margin0.28 %
Current Valuation1.93 B
Shares Outstanding51.32 M
Shares Owned By Insiders60.25 %
Shares Owned By Institutions17.46 %
Price To Earning15.16 X
Price To Book6.51 X

Currently Active Assets on Macroaxis

DDDupont De Nemours
CRDOCredo Technology Group
GOOGAlphabet Inc Class C
BACBank of America
CRMSalesforce

Other Information on Investing in Laboratorios Pink Sheet

Laboratorios Farmaceuticos financial ratios help investors to determine whether Laboratorios Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Laboratorios with respect to the benefits of owning Laboratorios Farmaceuticos security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY